BOSTON, Aug. 6, 2024 ~ Dotmatics, a leading provider of R&D scientific software, has announced a significant minority investment in BioGlyph, a startup biotech software company. This investment is aimed at supporting the development of technology that will visually illustrate, register, and model biologic molecules, with a specific focus on multispecific antibodies (MsAbs).

BioGlyph is known for its proprietary technology and exceptional talent in the field of MsAbs research and development. The company's expertise lies in accelerating and improving the development of protein therapeutics. With MsAbs being one of the fastest growing research modalities today, Dotmatics' investment in BioGlyph is a strategic move to support its customers who are pursuing new therapies using a multimodal approach to life science discovery.

MsAbs have the ability to bind two or more antigens, opening up new possibilities for therapeutic applications that traditional monoclonal antibodies cannot fulfill. This technology is crucial for bridging different cells or receptor proteins on the same cell, presenting groundbreaking opportunities in therapeutic development.

More on Boston Chron

• How to Fast-Track Your Way to the Top with The Code
• Lyricalmar Set To Release Powerful New Ep "MARCHIVES" May 16
• Charleston, SC - ACSEC offers Rain Barrels Through Annual Program
• Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
• Boston: Bridging the Digital Divide by Embedding Digital Skills in Workforce Development

According to Dotmatics CEO Thomas Swalla, this investment aligns with the growing demand from customers for software that supports MsAb formats. As drug discovery becomes more multidisciplinary, there is a need for advanced software that can keep up with new modalities. This led Dotmatics to introduce their new scientific intelligence platform, Luma, which allows scientists to connect old and new science in a way that enhances the precision and efficiency of antibody design and production.

BioGlyph is led by CEO and co-founder Fernando Garces, who previously served as director of Protein Therapeutics at Gilead Sciences and principal scientist at Amgen. The company's founder McClain Kressman is currently pursuing a PhD at the University of California, Santa Cruz. Avi Peltz also serves as a co-founder and leads software development at BioGlyph.

Garces explains that after 20 years in protein engineering, he recognized the limitations of traditional tools in keeping up with the increasing complexities of biotherapeutics, especially MsAbs. This led the BioGlyph team to develop a visual software solution that empowers protein engineers with creativity while managing registration, data labeling, and in-silico testing of MsAbs' fitness, among other functions. He believes that their software will empower R&D scientists to make better decisions that accelerate timelines and lower costs.

More on Boston Chron

• Baltimore Author Crafts Space Opera Where Human Questions Outshine Galactic Scale
• Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
• OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
• MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
• New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY

Kressman adds that working together with Dotmatics will help them bring this highly sought-after technology to market in an expedited manner. He also mentions their eagerness to harness the power of AI in life sciences and provide protein engineers with cutting-edge tools for the future.

However, it is important to note that this press release contains forward-looking statements and is intended for informational purposes only. It should not be relied upon for making purchase decisions as it does not guarantee any specific functionality or product release. The development, release, and timing of any products or capabilities remain at the sole discretion of Dotmatics.

Additionally, no representation or warranty is provided regarding the accuracy or reliability of the information expressed in this press release. Any legal effect will only be applicable if stated in one or more definitive agreements involving both parties.

---

Show All News | Report Violation